After radiosurgery concurrent with nivolumab in 59-year-old patient with melanoma BM (patient 1; Supplemental Tables 3 and 5), F-18 FET PET at follow-up 12 weeks after treatment initiation (bottom row) shows significant decrease of metabolic activity (TBRmean, ?28%) compared with baseline (top row), although MRI changes were consistent with progression according to iRANO criteria. Reduction of metabolic activity was associated with stable clinical course over 10 mo. CE = contrast-enhanced. Image created by N. Galldiks et al., Research Center Juelich, Juelich, Germany.
More from Imaging Technology News
Microsoft Acquires Nuance to Accelerate Its Healthcare Industry Cloud Strategy
Source Node: 808200
Time Stamp: Apr 12, 2021
RSIP Vision Unveils Metal Implant and Anatomical Segmentation Tool
Source Node: 799871
Time Stamp: Mar 24, 2021
Expanded AI-based Echocardiography Analysis and Reporting Added to Konica Minolta Exa Cardio PACS
Source Node: 747844
Time Stamp: Nov 13, 2020
Forbes AI 50 Selects Nines as one of the Most Promising AI Companies
Source Node: 845684
Time Stamp: May 6, 2021
Canon Medical Receives FDA Clearance on One-beat Spectral Cardiac CT
Source Node: 824674
Time Stamp: Apr 21, 2021